Analysts’ Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)
TipRanks (Wed, 8-May 12:00 AM ET)
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
Business Wire (Thu, 2-May 4:05 PM ET)
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
Business Wire (Tue, 30-Apr 4:05 PM ET)
Business Wire (Thu, 18-Apr 8:00 AM ET)
Business Wire (Thu, 11-Apr 4:30 PM ET)
Business Wire (Mon, 1-Apr 8:00 AM ET)
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
PRNewswire (Fri, 22-Mar 7:00 AM ET)
Business Wire (Tue, 5-Mar 8:05 AM ET)
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
Business Wire (Fri, 23-Feb 8:05 AM ET)
Business Wire (Thu, 22-Feb 4:05 PM ET)
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Vir Biotechnology trades on the NASDAQ stock market under the symbol VIR.
As of May 13, 2024, VIR stock price climbed to $9.73 with 316,934 million shares trading.
VIR has a beta of 1.68, meaning it tends to be more sensitive to market movements. VIR has a correlation of 0.09 to the broad based SPY ETF.
VIR has a market cap of $1.32 billion. This is considered a Small Cap stock.
In the last 3 years, VIR stock traded as high as $58.00 and as low as $7.61.
The top ETF exchange traded funds that VIR belongs to (by Net Assets): IJR, VTI, XBI, VB, IWM.
VIR stock has underperformed the market in the last year with a return of -60.2%, while SPY returned +27.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VIR shares. However, VIR has outperformed the market in the last 3 month and 2 week periods, returning +4.7% and +18.2%, while SPY returned +4.2% and +2.5%, respectively. This indicates VIR has been having a stronger performance recently.
VIR support price is $9.14 and resistance is $9.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VIR stock will trade within this expected range on the day.